Seattle Life Sciences
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Seattle Life Sciences
Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data
ZymoGenetics shareholders who want a better offer than the $885 million acquisition Bristol-Myers Squibb offered on Wednesday, September 8, aren’t likely to get one. It’s a disappointing result for a company with nearly 30 years of biotech discovery and grand ambitions behind it.
Deals Shaping the Medical Industry (07/2009)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice